Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Onto Innovation (ONTO) Price & Performance

Neurocrine Biosciences IncTrade
Onto InnovationTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Onto Innovation — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Onto Innovation trades at $294.96 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc and Onto Innovation are close in size by market cap, and Onto Innovation is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Onto Innovation for 5 Days on average.

NBIXONTO
Market Cap
$14.36B$14.36B
Volume
1,237,180761,617
Sector
HealthTechnology
52-Week High
$185.50$378.45
52-Week Low
$123.10$121.34
Typical Hold Time
23 Days5 Days
Enterprise Value
$14.37B$13.95B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.

The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.

Onto Innovation

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NBIX

No sentiment data available yet.

ONTO
100% Buy0% Sell
Avg holding period · 5 Days

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX →

About Onto Innovation

Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.

Read more on ONTO →